0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial

Barry R. Davis, MD, PhD; Jeffrey A. Cutler, MD; Curt D. Furberg, MD, PhD; Jackson T. Wright Jr., MD, PhD; Michael A. Farber, MD; James V. Felicetta, MD; John D. Stokes, MD, ALLHAT Collaborative Research Group*
[+] Article and Author Information

From the University of Texas School of Public Health, Houston, Texas; the National Heart, Lung, and Blood Institute, Bethesda, Maryland; Wake Forest University School of Medicine, Winston-Salem, North Carolina; Case Western Reserve University School of Medicine, Cleveland, Ohio; Pitman Internal Medicine Associates, Pitman, New Jersey; and Carl T. Hayden Veterans Affairs Medical Center, Phoenix, Arizona.


Grant Support: By contract NO-HC-35130 from the National Heart, Lung, and Blood Institute. Study medications were supplied by Pfizer, Inc. (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin); Pfizer, Inc., provided financial support to the National Heart, Lung, and Blood Institute.

Potential Financial Conflicts of Interest:Consultancies: B.R. Davis, J.T. Wright Jr., J.V. Felicetta; Honoraria: C.D. Furberg, J.T. Wright Jr., J.V. Felicetta; Stock Ownership: M.A. Farber; Grants Received: C.D. Furberg, J.T. Wright Jr., J.V. Felicetta.

Requests for Single Reprints: Barry R. Davis, MD, PhD, the University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030; e-mail, bdavis@sph.uth.tmc.edu.

Current Author Addresses: Dr. Davis: The University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030.

Dr. Cutler: The National, Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Bethesda, MD 20892.

Dr. Furberg: Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157.

Dr. Wright: Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106.

Dr. Farber: Pitman Internal Medicine Associates, 410 North Broadway, Pitman, NJ.

Dr. Felicetta: Carl T. Hayden Veterans Affairs Medical Center, 650 East Indian School Road, Phoenix, AZ 85012.

Dr. Stokes: 2323 Curlew Road, Palm Harbor, FL 34683.

Author Contributions: Conception and design: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright.

Analysis and interpretation of the data: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright.

Drafting of the article: B.R. Davis, J.A. Cutler, J.T. Wright, M.A. Farber.

Critical revision of the article for important intellectual content: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright, M.A. Farber, J.V. Felicetta, J.D. Stokes.

Final approval of the article: B.R. Davis, J.A. Cutler, C.D. Furberg, J.T. Wright, J.V. Felicetta.

Provision of study materials or patients: B.R. Davis, M.A. Farber, J.D. Stokes.

Statistical expertise: B.R. Davis.

Obtaining of funding: B.R. Davis, J.A. Cutler.

Administrative, technical, or logistic support: B.R. Davis, J.A. Cutler, C.D. Furberg.

Collection and assembly of data: B.R. Davis, J.V. Felicetta, J.D. Stokes.


Ann Intern Med. 2002;137(5_Part_1):313-320. doi:10.7326/0003-4819-137-5_Part_1-200209030-00006
Text Size: A A A

The results presented here are restricted to the same data set as the previously published analysis (1). The median duration of follow-up for all participants was 3.3 years. Five hundred (3.3%) patients in the chlorthalidone group and 338 (3.7%) patients in the doxazosin group were lost to follow-up. During the trial, about 59% of patients in the chlorthalidone group and 68% of patients in the doxazosin group were stepped up to additional drugs.

First Page Preview

View Large
First page PDF preview

Figures

Grahic Jump Location
Figure. Values in parentheses are percentages of total participants. *Patients discontinued from therapy with randomly assigned drug. ACE = angiotensin-converting enzyme; HF = heart failure.
Participants who underwent randomization and were followed in the monotherapy and open-label therapy analyses, by study treatment group.
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Blood Pressure Drugs and Heart Failure

The summary below is from the full report titled “Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.” It is in the 3 September 2002 issue of Annals of Internal Medicine (volume 137, pages 313-320). The authors are BR Davis, JA Cutler, CD Furberg, JT Wright Jr., MA Farber, JV Felicetta, and JD Stokes, for the ALLHAT Collaborative Research Group.

Read More...

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)